FDA Approves Verastem’s Ovarian Cancer Therapy for Some Adult Patients

It marks the first and only approval for a drug to treat adults with low-grade serous ovarian cancer.

The U.S. Food and Drug Administration building in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times

The Food and Drug Administration (FDA) has granted accelerated approval to biopharmaceutical company Verastem Oncology’s combination therapy for adults who have received prior treatment for a rare type of ovarian cancer, the regulator announced on Thursday.

The FDA approved Avmapki Fakzynja co-pack (avutometinib capsules; defactinib tablets) for patients with recurrent Kirsten rat sarcoma viral oncogene homolog (KRAS) mutated low-grade serous ovarian cancer (LGSOC) who received prior systemic therapy.